Hepatitis in the Renal Patient

  • David Roth
  • Guido Perez


In recent years, hepatitis C virus has loomed importantly as the primary cause of non-A, non-B hepatitis and as a clinical problem of growing significance. This concern applies not only to the population at large but also specifically to the ESRD population of dialysis and immunosuppressed allograft recipients. Indeed, the magnitude of this problem is reflected by the fact that HCV was barely mentioned in previous editions of this book and now merits a comprehensive chapter.


Dialysis Patient Hemodialysis Patient Chronic Active Hepatitis Chronic Persistent Hepatitis Essential Mixed Cryoglobulinemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Aach RD, Stevens CE, Hollinger FB, Mosley JW, Peterson DA, Taylor PE, Johnson RG, Barbosa LH, Nemo GJ: Hepatitis C virus infection in post-transfusion hepatitis. An analysis with first and second-generation assays. N Engl J Med 325: 1325–1329, 1991.PubMedCrossRefGoogle Scholar
  2. 2.
    Alter HJ, Purcell RH, Shih SW, Melpolder JC, Houghton M, Choo Q-L, Kuo G: Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 321: 1494–1500, 1989.PubMedCrossRefGoogle Scholar
  3. 3.
    Houghton M, Weiner A, Han J, Kuo G, Choo Q-L: Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease. Hepatology 14: 381–388, 1991.PubMedCrossRefGoogle Scholar
  4. 4.
    Esteban JI, Gonzalez A, Hernandez JM, Vildomiu L, Sánchez C, López-Talavera JC, Lucea D, Martin-Vega C, Vidal X, Esteban R, Guardia J: Evaluation of antibodies to hepatitis C virus in a study of transfusion associated hepatitis. N Engl J Med 323: 1107–1112, 1990.PubMedCrossRefGoogle Scholar
  5. 5.
    Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, Hu PY, Miller JK, Gerber MA, Sampliner RE, Meeks EL, Beach MJ: The natural history of community-acquired hepatitis C in the United States. N Engl J Med 327: 1899–1905, 1992.PubMedCrossRefGoogle Scholar
  6. 6.
    Roth D, Zucker K, Cirocco R, Demattos A, Burke GW, Nery J, Esquenazi V, Babischkin S, Miller J: The impact of hepatitis C virus infection on renal allograft recipients. Kidney Int 45: 238–244, 1994.PubMedCrossRefGoogle Scholar
  7. 7.
    Pol S, Romeo R, Zins B, Driss F, Lebkiri B, Carnot F, Berthelot P, Brichot C: Hepatitis C virus RNA in anti-HCV positive hemodialysis patients: significance and therapeutic implications. Kideny Int 44: 1097–1100, 1993.CrossRefGoogle Scholar
  8. 8.
    Chan TM, Lok ASF, Cheng IKP, Chan RT: Prevalence of hepatitis C virus infection in hemodialysis patients: a longitudinal study comparing the results of RNA and antibody assays. Hepatology 17: 5–8, 1993.PubMedCrossRefGoogle Scholar
  9. 9.
    Tsukarma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi Y, Kitamura T, Nakanishi K, Fujimoto I, Inoue A, Yamazaki H, Kawashima T: Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 328: 1797–1801, 1993.CrossRefGoogle Scholar
  10. 10.
    Kuo G, Choo Q-L, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, Miyamura T, Dienstag JL, Alter JM, Stevens CE, Tegtmeier GE, Bonino F, Colombo M, Lee W-S, Kuo C, Berger K, Shuster JR, Overby LR, Bradley DW, Houghton M: An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 244: 362–364, 1989.PubMedCrossRefGoogle Scholar
  11. 11.
    Garson JA, Tedder RS, Briggs M, Tuke P, Glazebrook JA, Trute A, Parker D, Barbara JAJ, Contreras M, Aloysius S: Detection of hepatitis C viral sequences in blood donations by “nested” polymerase chain reaction and prediction of in-fectivity. Lancet 335: 1419–1422, 1990.PubMedCrossRefGoogle Scholar
  12. 12.
    McGuinness PH, Bishop GA, Lien A, Wiley B, Parsons C, McCaughan AW: Detection of serum hepatitis C virus RNA in HCV antibody-seropositive volunteer blood donors. Hepatology 18: 485–490, 1993.PubMedCrossRefGoogle Scholar
  13. 13.
    Donahue JG, Munoz A, Ness PM, Brown DE, Yawn DN, Mcallister HA, Reitz BA, Nelson KE: The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med 327: 369–373, 1992.PubMedCrossRefGoogle Scholar
  14. 14.
    Alberti A, Chemello L, Cavaletto D, Tagger A, Canton A, Bizzaro N, Tagariello G, Ruol A: Antibody to hepatitis C virus and liver disease in volunteer blood donors. Ann Intern Med 114: 1010–1012, 1991.PubMedCrossRefGoogle Scholar
  15. 15.
    McFarlane IG, Smith HM, Johnson PJ, Bray GP, Vergani D, Williams R: Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false-positive result? Lancet 335: 754–757, 1990.PubMedCrossRefGoogle Scholar
  16. 16.
    Farci P, London WT, Wong DC, Dawson GJ, Vallari DS, Engle R, Purcell RH: The natural history of infection with hepatitis C virus in chimpanzees: comparison of serologic responses measured with first and second generation assays and relationship to HCV viremia. J Infect Dis 165: 1006–1011, 1992.PubMedCrossRefGoogle Scholar
  17. 17.
    McHutchison JG, Person JL, Govindarajan S, Valinluck B, Gore T, Lee SR, Nelles M, Polito A, Chien D, DiNello R, Quan S, Kuo G, Redeker AG: Improved detection of hepatitis C virus antibodies in high-risk populations. Hepatology 15: 19–25, 1992.PubMedCrossRefGoogle Scholar
  18. 18.
    VanderPoel CL, Cuypers HTM, Reesink HW, Weiner AJ, Quan S, DiNello R, Boven JJP, Winkel I, Mulder-Folkerts D, Exel-Oehlers PJ, Schaasberg W, Leentvaar-Kuypers A, Polito A, Houghton M, Lelie P: Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay. Lancet 337: 317–319, 1991.CrossRefGoogle Scholar
  19. 19.
    Esteban JI, Löpez-Talavera JC, Genesca J, Madoz P, Viladomiu L, Muniz E, Martin-Vega C, Rosell M, Allende H, Vidal X, Gonzalez A, Hernandez M, Esteban R, Guardia J: High rate of infectivity and liver disease in blood donors with antibodies to hepatitis C virus. Ann Intern Med 115: 443–449, 1991.PubMedCrossRefGoogle Scholar
  20. 20.
    Broyer M, Brunner FP, Brynger H, Fassbinder W, Guidlou PJ, Oules R, Rizzoni G, Seiwood NH, Wing AJ: Combined report on regular dialysis and transplantation in Europe. Proc Eur Dial Transplant Assoc 16: 50–52, 1985.Google Scholar
  21. 21.
    Shusterman N, Singer I: Infectious hepatitis in dialysis patients. Am J Kidney Dis 9: 447–455, 1987.PubMedGoogle Scholar
  22. 22.
    Parfrey PS, Farge D, Forbes RD, Dandavino R, Kenick S, Guttman RD: Chronic hepatitis in end-stage renal disease: comparison of HBsAg-negative and HBsAg-positive patients. Kidney Int 28: 959–967, 1985.PubMedCrossRefGoogle Scholar
  23. 23.
    Koretz RL, Stone O, Mousa M, Gitnick G: The pursuit of hepatitis in dialysis units. Am J Nephrol 4: 222–226, 1984.PubMedCrossRefGoogle Scholar
  24. 24.
    Polakoff S: Hepatitis in dialysis units in the United Kingdom. A Public Health Laboratory Service Survey. J Hyg (Lond) 87: 443–451, 1981.CrossRefGoogle Scholar
  25. 25.
    Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M: Isolation of a c-DNA clone derived from blood borne viral hepatitis genome. Science 244: 262–264, 1989.CrossRefGoogle Scholar
  26. 26.
    Choo QL, Weiner AJ, Overby, Kuo G, Houghton M, Bradley DW: Hepatitis C virus, the major causative agent for viral NANB hepatitis. Br Med Bull 46: 423–441, 1990.PubMedGoogle Scholar
  27. 27.
    Esteban JI, Esteban R, Viladomiu L, Gonzalez A, Lopez- Talavera JC, Conzalez A, Hernandez JM, Roget M, Vargas V, Genesca J, Buti M, Guardia J: Hepatitis C virus antibodies among risk groups in Spain. Lancet 2: 294–297, 1989.PubMedCrossRefGoogle Scholar
  28. 28.
    Kuhnl P, Roggendorf M, Sibrowski W, Deinhardt F, Laufs R, Bornhovd K, Kalmar G, Seidl S, Böhm BO: Hepatitis C virus antibodies (HCV) in patients treated with chronic hemodialysis. Beitr Infusionther 26: 27–29, 1990.PubMedGoogle Scholar
  29. 29.
    Jeffers LJ, Perez GO, de Medina MD, Ortiz-Interian CJ, Schiff ER, Reddy KR, Jimenez M, Bourgoignie JJ, Vaamonde CA, Duncan R, Houghton M, Choo QL, Kuo G: Hepatitis C infection in two urban hemodialysis units. Kidney Int 38: 320–322, 1990.PubMedCrossRefGoogle Scholar
  30. 30.
    Gilli P, Moretti M, Soffritti SM, Marchi N, Malacarne F, Bedani PL, DePaoli Vitali E, Fiocchi O, Menini C: Non-A, non-B hepatitis and anti-HCV antibodies in dialysis patients. Int J Artif Organs 13: 737–741, 1990.PubMedGoogle Scholar
  31. 31.
    Zeldis J, Depner T, Kuramoto I, Gish, Holland P: The prevalence of hepatitis C virus antibodies among hemodialysis patients. Ann Intern Med 112: 958–960, 1990.PubMedCrossRefGoogle Scholar
  32. 32.
    Fairley CK, Leslie DE, Nicholson S, Gust: Epidemiology and hepatitis C virus in Victoria. Med J Aust 153: 271–273, 1990.PubMedGoogle Scholar
  33. 33.
    Teruel JL, Fernandez Munoz R, Gamez C, Mareen A, Celma ML, Liano F, Ortuno J: Hepatitis C virus infection in patients treated by hemodialysis. Med Clin (Bare) 95: 81–83, 1990.Google Scholar
  34. 34.
    Oguchi H, Miyasaka M, Tokunaga S, Hora K, Ichikawa S, Ochi T, Yamada K, Nagasawa M, Kanno Y, Aizawa T, Watanabe H, Yoshizawa S, Sato K, Terashima M, Yoshie T, Oguchi S, Tanaka E, Kiyosawa K, Furuta S: Hepatitis virus infection (HBV and HCV) in eleven Japanese hemodialysis units. Clin Nephro 38: 36–43, 1992.Google Scholar
  35. 35.
    letter to the editor). Lancet 335: 1409, 1990.Google Scholar
  36. 36.
    letter to the editor). Lancet 335: 1409, 1990.Google Scholar
  37. 37.
    Lai KN, Tam JS, Llai FM, Lin HJ: Isolated presence of antibody to hepatitis B core antigen in dialysis patients: occurrence of subclinical hepatitis C. Am J Kidney Dis 13: 370–376, 1989.PubMedGoogle Scholar
  38. 38.
    de Medina M, Ortiz C, Krenc C, Leete J, Vallari D, Hill M, LaRue S, Jimenez M, Anderson W, Schiff E, Perez G: Improved detection of antibodies to hepatitis C virus in dialysis patients using a second-generation enzyme immunoassay. Am J Kidney Dis 20: 589–591, 1992.PubMedGoogle Scholar
  39. 39.
    Mondelli MU, Cristina G, Piazza V, Cerino A, Villa G, Salvadeo A: High prevelance of antibodies to hepatitis C virus in hemodialysis units using a second generation assay. Nephron 61: 350–351, 1992.PubMedCrossRefGoogle Scholar
  40. 40.
    Cantu P, Mangano S, Masini M, Limido A, Crovetti G, DeFilippo C: Prevalence of antibodies against hepatitis C virus in a dialysis unit. Nephron 61: 337–338, 1992.PubMedCrossRefGoogle Scholar
  41. 41.
    Polywka S, Kaars Wiele P, Schroeter E, Mandler J, Laufs R: Detection of antibodies to HCV: Comparison of a cl00–3 EIA and the 2nd generation EIA. Beitr Infusionther 30: 42–45, 1992.PubMedGoogle Scholar
  42. 42.
    Holzberger G, Seidl S, Peschke B, Scheuermann EH, Schoeppe W: Decreasing the risk of post-tranfusion non-A, non-B hepatitis by anti-HCV screening. Beitr Infusionther 30: 46–48, 1992.PubMedGoogle Scholar
  43. 43.
    Chauveau P, Courouce AM, Lemarec N, Naret C, Poignet JL, Girault A, Ramdame M, Delons S: Antibodies to hepatitis C virus by second generation test in hemodialyzed patients. Kidney Int Suppl 41: 149–152, 1993.Google Scholar
  44. 44.
    Knudsen F, Wantzin P, Rasmussen K, Ladefoged SD, Lokkegaard N, Rasmussen LS, Lassen A, Krogsgaard K: Hepatitis C in dialysis patients: relationship to blood transfusion, dialysis, and liver disease. Kidney Int 43: 1353–1356, 1993.PubMedCrossRefGoogle Scholar
  45. 45.
    Dentico P, Volpe A, Buongiorno R, Fiore G, Carbone M, Manno C, Pastore G, Schiraldi O: Detection of antibodies to HCV in hemodialysis patients using two second generation ELISA tests, ltal I Gastroenterol 25: 19–22, 1993.Google Scholar
  46. 46.
    Chan TM, Lok AS, Cheng IK: Hepatitis C infection among dialysis patients: a comparison between patients on maintenance hemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 6: 944–947, 1991.PubMedCrossRefGoogle Scholar
  47. 47.
    Huang CC, Wu MS, Lin DY, Liaw YF: The prevalence of hepatitis C virus antibodies in patients treated with continuous ambulatory peritoneal dialysis. Perit Dial Int 12: 31–33, 1992.PubMedGoogle Scholar
  48. 48.
    Selgas R, Martinez-Zapico R, Bajo MA, Romero JR, Munoz J, Rinon C, Miranda B, Miquel JL: Prevalence of hepatitis C antibodies (HCV) in a dialysis population at one center. Perit Dial Int 12: 28–30, 1992.PubMedGoogle Scholar
  49. 49.
    Ng YY, Lee SD, Wu SC, Liu WT, Chia WL, Huang TP: The need for second generation anti-hepatitis C virus testing in uremic patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 13: 132–135, 1993.PubMedGoogle Scholar
  50. 50.
    Kuhns M, de Medina M, McNamara A, Jeffers LJ, Reddy ER, Silva M, Ortiz-Interian C, Jimenez M, Schiff E, Perez G: Detection of hepatitis C virus in hemodialysis patients. J Am Soc Nephrol 4: 1491–1497, 1994.PubMedGoogle Scholar
  51. 51.
    Li JS: Hepatitis C virus infection in hemodialysis patients. Chung Hua I Hsueh Tsa Chih 72: 655–701, 1992.PubMedGoogle Scholar
  52. 52.
    Sheu JC, Lee SH, Wang JT, Shih LN, Wang TH, Chen DS: Prevalence of anti-HCV and HCV viremia in hemodialysis patients in Taiwan./Med Virol 37: 108–112, 1992.Google Scholar
  53. 53.
    Sakamoto N, Enomoto N, Marumo F, Sato C: Prevalence of hepatitis C virus infection among long-term hemodialysis patients: detection of hepatitis C virus RNA in hemodialysis patients. J Med Virol 39: 11–15, 1993.PubMedCrossRefGoogle Scholar
  54. 54.
    Dussol B, Chicheportiche C, Cantaloube JF, Roubicek C, Biagini P, Berland Y: Detection of hepatitis C infection by polymerase chain reaction among hemo-dialysis patients. Am J Kidney Dis 22: 574–580, 1993.PubMedGoogle Scholar
  55. 55.
    Farci P, Alter H, Wong D, Miller R, Shih J, Jett B, Purcell R: A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med 325: 98–104, 1991.PubMedCrossRefGoogle Scholar
  56. 56.
    Kato N, Yokosuka O, Omata M, Hosoda K, Ohto M: Detection of hepatitis C virus ribonucleic acid in the serum by amplification with polymerase chain reaction. J Clin Invest 86: 1764–1767, 1990.PubMedCrossRefGoogle Scholar
  57. 57.
    Ulrich P, Romeo J, Lane P, Kelly 1, Daniel L, Vyas G: Detection, semiquantitation, and genetic variation in hepatitis C virus sequences amplified from the plasma of blood donors with elevated alanine aminotransferase. J Clin Invest 86: 1609–1614, 1990.PubMedCrossRefGoogle Scholar
  58. 58.
    de Medina M, LaRue S, Hill M, Hunt W, Urdes M, Wilber JC, Johnson P, Xi XM, Jeffers LJ, Parker T, Reedy KR, Schiff ER, Perez G: Quantitative detection of hepatitis C virus in patients undergoing hemodialysis. ASAIO Journal 43: 19–22, 1997.PubMedGoogle Scholar
  59. 59.
    Lau J YN, Davis GL, Kniffen J, Oian KP, Urdia M, Chan C, Mizokami M, Neuwald PD, Wiber JC: Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 341: 1505–1508, 1993.CrossRefGoogle Scholar
  60. 60.
    Hagiwara H, Hayashi N, Mita E, Takehara T, Kasahara A, Fusamoto H, Kamada T: Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology 104: 877–883, 1993.PubMedGoogle Scholar
  61. 61.
    Favero M, Alter M, Bland L: In: JV Bennett, B Brachman, eds, Hospital Infections, 3rd ed. Little, Brown, Boston, 19:375-03.Google Scholar
  62. 62.
    Dentico P, Buongiorno R, Volpe A, Carlone A, Carbone M, Manno C, Proscia F, Pastore G, Schiraldi O: The prevalence and incidence of hepatitis C virus (HCV) in hemodialysis patients: study of risk factors. Clin Nephrol 38: 49–52, 1992.PubMedGoogle Scholar
  63. 63.
    Jadoul M, Corner CH, Van Ypersele de Strihou CH, and the UCL collaborative group: Incidence and risk factors for hepatitis C seroconversion in hemodialysis: a prospective study. Kidney Int 44: 1322–1326, 1993.Google Scholar
  64. 64.
    Niu MT, Coleman PJ, Alter MJ: Multicenter study of hepatitis C virus infection in chronic hemodialysis patients and hemodialysis center staff members. J Am Soc Nephrol 22: 568–573, 1993.Google Scholar
  65. 65.
    Hardy NM, Sandroni S, Danielson S, Wilson WJ: Antibody to hepatitis C virus increases with time on hemodialysis. Clin Nephrol 38: 44–48, 1992.PubMedGoogle Scholar
  66. 66.
    Willems M, de Jong G, Moshage H, Verresen L, Goubau P, Desmyter J, Yap SH: Surrogate markers are not useful for identification of HCV carriers in chronic hemodialysis patients. J Med Virol 35: 303–306, 1991.PubMedCrossRefGoogle Scholar
  67. 67.
    Gitnick G, Weiss S, Overby LR, Ling CM, Chairez R, Parsa K: Non-A, non-B hepatitis: a prospective study of a hemodialysis outbreak with evaluation of a serologic marker in patients and staff. Hepatology 3: 625–630, 1983.PubMedCrossRefGoogle Scholar
  68. 68.
    Chiaramonte S, Tagger A, Ribero ML, Grossi A, Milan M, La Greca G: Prevention of viral hepatitis in dialysis units: isolation and technical management of dialysis. Nephron 61: 287–289, 1992.PubMedCrossRefGoogle Scholar
  69. 69.
    Marchesi D, Arici C, Poletti E, Mingardi G, Minola E, Mecca G: Outbreak of non-A, non-B hepatitis in centre hemodialysis patients: a retrospective analysis. Nephrol Dial Transplant 3: 795–799, 1988.PubMedGoogle Scholar
  70. 70.
    Niu MT Alter MJ, Kristensen C, Margolis HS: Outbreak of hemodialysis-associated non-A, non-B hepatitis and correlation with antibody to hepatitis C virus. Am J Kidney Dis 19: 345–352, 1992.PubMedGoogle Scholar
  71. 70a.
    Stuyver L, Claeys H, Wysecer A, Arnherm WV, De Beenhouwer H, Uytendaele S, Beckers J, Matthys D, Leroux-Roels G, Maertens G, De Paepe M: Hepatitis Cuirus in hemodialysis unit: Molecular evidence for nosocomial transmission, Kidney Intt 49: 889–895, 1996.CrossRefGoogle Scholar
  72. 70b.
    Olmer M, Bouchouareb D, Zandotti C, de Mico P, de Lamballerie X: Transmission of the hepatitis B in a hemodialysis unit. Clin Nephrol 47: 265–270, 1996.Google Scholar
  73. 71.
    Garcia-Valdecasas, J Bernal MC, Cerezo, Garcia F, Pereira BJG: Strategies to reduce the transmission of HCV infection in hemodialysis (HD) units. J Am Soc Nephrol 4: 347, 1993.Google Scholar
  74. 72.
    Conway M, Catterall AP, Brown EA, Tibbs C, Gower PE, Curtis JR, Coleman JC, Murray-Lyon IM: Prevalence of antibodies to hepatitis C in dialysis patients and transplant recipients with possible routes of transmission. Nephrol Dial Transplant 7: 1226–1229, 1992.PubMedGoogle Scholar
  75. 73.
    Everhart JE, Di Bisceglie AM, Murray LM, Alter HJ, Melpolder JJ, Kuo G, Hoofnagle JH: Risk for non-A, non-B (type C) hepatitis through sexual or household contact with chronic carriers. Ann Intern Med 112: 544–545, 1990.PubMedCrossRefGoogle Scholar
  76. 74.
    Riestra S, Carcaba V: Hepatitis C virus; evidence for sexual transmission. Br Med J 303: 301–311, 1991.CrossRefGoogle Scholar
  77. 75.
    Sanchez-Quijano A, Rey C, Aguado I, Pineda JA, Perez Romero M, Torres Y, Leal M, Lissen E: Hepatitis C infection in a sexually promiscuous group. Eur J Clin Microbiol Infect Dis 9: 610–612, 1990.PubMedCrossRefGoogle Scholar
  78. 76.
    Hess G, Massing A, Rossol S, Shutt H, Clemens R, Meyer-zum-Buschenfelde KH: Hepatitis C virus and sexual transmission. Lancet 2: 987, 1989.PubMedCrossRefGoogle Scholar
  79. 77.
    Kamitsukasa H, Harada H, Yakura M, Fukuda A, Ohbayashi A, Saito I, Miyamura T, Choo OL, Houghton M, Kuo G: Intrafamilial transmission of hepatitis C virus. Lancet 2: 98, 1989.Google Scholar
  80. 78.
    Ideo G, Bellati G, Pedraglio E, Bottelli R, Donzelli T, Putignano G: Intrafamilial transmission of hepatitis C virus. Lancet 1: 353, 1990.CrossRefGoogle Scholar
  81. 79.
    Alfurayh O, Sobh M, Buali A, Ali MA, Barri Y, Ounibi W, Taher S: Hepatitis C virus infection in chronic hemodialysis patients, a clinicopathologic study. Nephrol Dial Transplant 4: 327–332, 1992.Google Scholar
  82. 80.
    Gilli P, Cavazzini L, Stabellini N, Malacarne F, Soffritti S, Storari A: Histological features of non-A, non-B hepatitis in hemodialysis patients. Nephron 61: 296–297, 1992.PubMedCrossRefGoogle Scholar
  83. 81.
    Caramelo C, Ortiz A, Aguilera B, Porres JC, Navas S, Marriott E, Alberola ML, Alamo C, Galera A, Garron MP, Gonzalez-Parra E, Fernandez de Gabriel MV, Oliva H, Carreno V: Liver disease in hemodialysis patients with antibodies to hepatitis C virus. Am J Kidney Dis 22: 822–828, 1993.PubMedGoogle Scholar
  84. 82.
    Rao KV, Anderson WR, Kasiske BL, Dahl DC: Value of liver biopsy in the evaluation and management of chronic liver disease in renal transplant recipients. Am J Med 94: 241–250, 1993.PubMedCrossRefGoogle Scholar
  85. 83.
    Davis GL, Balart LA, Schiff ER, Lindsay K, Jacobson IM, Payne J, Dienstag JL, VanTheil DH, Tamburro C, Lefkowitch J, Albrecht J, Meschievitz C, Ortego TJ, Gibas A, and the Hepatitis Interventional Therapy Group: Treatment of chronic hepatitis C with recombinant interferon alpha: a multicenter randomized, controlled trial. N Engl J Med 321: 1501–1506, 1989.Google Scholar
  86. 84.
    DiBisceglie AM, Martin P, Kassianides C, Llisker MM, Goodman Z, Banks SM, Hoofnagle JH: A randomized, double-blind, placebo-controlled trial of recombinant human alpha-interferon therapy for chronic non-A, non-B (type C) hepatitis. Hepatology 11: S36 - S42, 1990.Google Scholar
  87. 85.
    Shindo M, DiBisceglie AM, Cheung L, Shih JW, Cristiano K, Feinstone SM, Hoofnagle JH: Decrease in serum hepatitis C viral RNA during alpha interferon therapy for chronic hepatitis C. Ann Intern Med 115: 700–704, 1991.PubMedCrossRefGoogle Scholar
  88. 86.
    McDonald J, Caruso L: Diminished responsiveness of male homosexual chronic hepatitis B virus carriers with HTLV-III antibodies to recombinant alpha interferon. Hepatology 7: 719–723, 1987.PubMedCrossRefGoogle Scholar
  89. 87.
    Koenig P, Umlauft F, Lhotta K, Weyrer K, Neyer U, Stummvoll HK, Vogel W, Brommeger R, Gruenewald K: Treatment of hemodialysis patients suffering from chronic HCV infection with interferon alpha. J Am Soc Nephrol 4: 361, 1993.Google Scholar
  90. 87a.
    Ellis ME, Alfurayh O, Nalim MA, Sieck JO, Ali MA, Bermvil SS, Ali H, Barri Y, Ayub A, al Fadda M: Chronic non-A, non-B hepatitis complicated by end-stage renal failure treated with recombinant interferon alpha. J Hepatol 18: 210–216, 1993.PubMedCrossRefGoogle Scholar
  91. 87b.
    Pol S, Thiers V, Carnot F, Zins B, Romeo R, Berthelot P, Brechot C: Efficacy and tolerance of a-2b interferon therapy on HCV intection of hemodialyzed patients. Kidney Int 47: 1412–1418, 1995.PubMedCrossRefGoogle Scholar
  92. 87c.
    Raptopoulou-Gigi M, Spaia S, Garifallos A, Xerou P, Orphanou H, Zarafidou E, Petridou P, Vrettou H, Vagioras G, Galakitidou G, Mauroudi I, Efkarpidou A, Kortsaris A: Interferon a-2b treatment of chronic hepatitis C in hemodialysis patients. Nephrol Dial Transplant 10: 1834–1837, 1995.PubMedGoogle Scholar
  93. 88.
    Weir MR, Kirkman RL, Strom TB, Tilney NL: Liver disease in recipients of long-functioning renal allografts. Kidney Int 28: 839–844, 1985.PubMedCrossRefGoogle Scholar
  94. 89.
    Boyce NW, Holdsworth SR, Hooke D, Thompson NM, Atkins RC: Non hepatitis B-associated liver disease in a renal transplant population. Am J Kidney Dis 11: 307–312, 1988.PubMedGoogle Scholar
  95. 90.
    LaQuaglia MP, Tolkoff-Rubin NE, Dienstag JL, Dienstag JL, Cosimi B, Herrin JT, Kelly M, Rubin RH: Impact of hepatitis on renal transplantation. Transplantation 32: 504–507, 1981.PubMedCrossRefGoogle Scholar
  96. 91.
    Morales M, Campo C, Castellano G, Colina F, Andres A, Fuertes A, Praga M, Rodicio JL: Clinical implications of the presence of antibodies to hepatitis C after renal transplantation. Transplant Proc 24: 78–80, 1992.PubMedGoogle Scholar
  97. 92.
    Pol S, Legendre C, Saltiel C, Carnot F, Brechot C, Berthelot P, Mattlinger B, Kreis H: Hepatitis C virus in kidney recipients: epidemiology and impact on renal transplantation. J Hepatol 15: 202–206, 1992.PubMedCrossRefGoogle Scholar
  98. 93.
    Pereira BJG, Milford EL, Kirkman RL, Levey AS: Transmission of hepatitis C virus by organ transplantation. N Engl J Med 325: 454–160, 1991.PubMedCrossRefGoogle Scholar
  99. 94.
    Roth D, Fernandez JA, Babischkin S, Demattos A, Buck BE, Quan S, Olson L, Burke GW, Nery J, Esquenazi V, Schiff ER, Miller J: Detection of hepatitis C virus infection among cadaver organ donors: evidence for low transmission of disease. Ann Intern Med 117: 470–475, 1992.PubMedCrossRefGoogle Scholar
  100. 95.
    Pereira BJG, Kirkman RL, Wright TL, Wright TL, Bryan CF, Cooper ES, Griffith JL, Kelly MK, Light JA, Norman DJ, Schmid C, Van Thiel D, Werner BG, Wright CE, Levey AS: National collaborative study of anti-HCV in cadaver donors: reduced organ wastage using a second generation anti-HCV test. J Am Soc Nephrol 3: 875A, 1992.Google Scholar
  101. 96.
    Pereira BJG, Milford EL, Kirkman RL, Quan S, Sayre KR, Johnson PJ, Wilber JC, Levey AS: Prevalence of hepatitis C virus RNA in organ donors positive for hepatitis C antibody and in the recipients of their organs. N Engl J Med 327:910-Google Scholar
  102. 97.
    Zucker K, Cirocco R, Roth D, Olson L, Burke GW, Nery J, Esquenzai V, Miller J: Depletion of hepatitis C virus from procured kidneys using pulsatile perfusion preservation. Transplantation 57: 832–840, 1994.PubMedCrossRefGoogle Scholar
  103. 98.
    Roth D, Fernandez JA, Burke GW, Esquenazi V, Miller J: Detection of antibody to hepatitis C virus in renal transplant recipients. Transplantation 51: 396–400, 1991.PubMedCrossRefGoogle Scholar
  104. 99.
    Ponz E, Campistol JM, Bruguera M, Barrera JM, Gil C, Pinto JB, Andreu J: Hepatitis C virus infection among kidney transplant recipients. Kidney Int 40: 748–751, 1991.PubMedCrossRefGoogle Scholar
  105. 100.
    Baur P, Daniel V, Pomer S, Scheurlen H, Opelz G, Roelcke D: Hepatitis C virus antibodies in patients after kidney transplantation. Ann Hematol 62: 68–73, 1991.PubMedCrossRefGoogle Scholar
  106. 101.
    Klauser R, Franz O, Traindl O, Pidlich J, Hay U, Watschinger B, Pohanka E, Kovank J: Hepatitis C antibody in renal transplant patients. Transplant Proc 24: 286–288, 1992.PubMedGoogle Scholar
  107. 102.
    Stempel CA, Lake J, Kuo G, Vincenti F: Hepatitis C—its prevalence in end-stage renal failure patients and clinical course after kidney transplantation. Transplantation 55:273-Google Scholar
  108. 103.
    Chan T-M, Lok AS, Cheng KP, Chan RT: A prospective study of hepatitis C infection among renal transplant recipients. Gastroenterology 104: 862–868, 1993.PubMedGoogle Scholar
  109. 104.
    Huang C-C, Liaw Y-F, Lai M-K, Chu S-H, Chuang C-K, Huang J-Y: The clinical outcome of hepatitis C virus antibody-positive renal allograft recipients. Transplantation 53: 763–765, 1992.PubMedCrossRefGoogle Scholar
  110. 105.
    Takamizawa A, Mori C, Fuke I, Manabe S, Murakami S, Fujita J, Onishi E, Andoh T, Yoshida I, Okayama H: Structure and organization of the hepatitis C virus genome isolated from human carries. J Virology 65: 1105–1113, 1991.PubMedGoogle Scholar
  111. 106.
    Nishioka K, Watanabe J, Furuta S, Tanaka E, lino S, Suzuki H, Tsuji T, Yano M, Kuo G, Choo Q, Houghton M, Oda T: A high prevalence of antibody to hepatitis C virus in patients with hepatocellular carcinoma in Japan. Cancer 67:429–433Google Scholar
  112. 107.
    Arita S, Asano T, Suzuki T, Enomoto K, Kobayashi S, Kenmochi T, Ochiai T, Isono K, Sakamota K: Clinical study of hepatitis disorders in renal transplant recipients with special reference to hepatitis C. Transplant Proc 24:1538–1540Google Scholar
  113. 108.
    Chan TM, Lok ASF, Cheng IKP: Hepatitis C in renal transplant recipients. Transplantation 52: 810–813, 1991.PubMedCrossRefGoogle Scholar
  114. 109.
    Linnemann CC, Kaufman CA, First MR, Schiff GM, Phair JP: Cellular immune response to cytomegalovirus infection after renal transplantation. Infect Immunol 22: 176–180, 1978.Google Scholar
  115. 110.
    Rytel MW, Aguilar-Torres FG, Balay J, Heim LR: Assessment of the status of cell mediated immunity in cytomegalovirus infected renal allograft recipients. Cell Immunol 37: 31–40, 1978.PubMedCrossRefGoogle Scholar
  116. 111.
    Pouteil-Noble C, Ecochard R, Landrivon G, Hart J, Bacchi CE, Hartwell P, Couser WG, Corey L, Wener MH, Alpers CE, Weilson R: Cytomegalovirus infection—an etiological factor for rejection? Transplantation 55: 851–857, 1993.PubMedCrossRefGoogle Scholar
  117. 112.
    Rollino C, Roccatello D, Giachino O, Basolo B, Piccoli G: Hepatitis C virus infection and membranous glomerulonephritis. Nephron 59: 319–320, 1991.PubMedCrossRefGoogle Scholar
  118. 113.
    Davda R, Peterson J, Weiner R, Croker B, Lau JY: Membranous glomerulonephritis in association with hepatitis C virus infection. Am J Kidney Dis 22: 452–455, 1993.PubMedGoogle Scholar
  119. 114.
    Johnson RJ, Gretch DR, Yamabe H, Hart J, Bacchi CE, Hartwell P, Couser WG, Corey L, Wener MH, Alpers CE, Wilson R: Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 328: 465–470, 1993.PubMedCrossRefGoogle Scholar
  120. 115.
    Cottiero R, Westrick E, Weinberg M: Membranoproliferative glomerulonephritis type I associated with chronic hepatitis C virus infection. J Am Soc Nephrol 3: 309A, 1992.Google Scholar
  121. 116.
    Burstein DM, Rodby RA: Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. J Am Soc Nephrol 4: 1288–1293, 1993.PubMedGoogle Scholar
  122. 117.
    D’Amico G, Colasanti G, Ferrario F, Sinico RA: Renal involvement in essential mixed cryoglobulinemia. Kidney Int 35: 1004–1014, 1989.PubMedCrossRefGoogle Scholar
  123. 118.
    Agnello V, Chung RT, Kaplan LM: A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 327: 1490–1495, 1992.PubMedCrossRefGoogle Scholar
  124. 119.
    Misiani R, Bellavita P, Fenili D, Borelli G, Marchesi D, Massazza M, Vendramin G, Comotti B, Tanzi E, Ssudella G, Zanetti A: Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann Intern Med 117: 573–577, 1992.PubMedCrossRefGoogle Scholar
  125. 120.
    Disdier P, Harlé J-R, Weiller P-J: Cryoglobulinemia and hepatitis C infection. Lancet 338: 1151–1152, 1991.PubMedCrossRefGoogle Scholar
  126. 121.
    Dammacco F, Sansonno D: Antibodies to hepatitis C virus in essential mixed cryoglobulinemia. Clin Exp Immunol 87: 352–356, 1992.PubMedCrossRefGoogle Scholar
  127. 122.
    Galli M, Monti G, Monteverde A: Hepatitis C virus and mixed cryoglobulinemias. Lancet 1: 989, 1992.CrossRefGoogle Scholar
  128. 123.
    Ferri C, Greco F, Longobardo G: Antibodies to hepatitis C virus in patients with mixed cryoglobulinemia. Arthritis Rheum 34: 1606–1610, 1991.PubMedCrossRefGoogle Scholar
  129. 124.
    Pechére-Bertschi A, Perrin L, de Saussure P, Widmann JJ, Giostra E, Schifterli JA: Hepatitis C: a possible etiology for cryoglobulinemia type II. Clin Exp Immunol 89: 419–422, 1992.PubMedCrossRefGoogle Scholar
  130. 125.
    Bonomo L, Casato M, Afeltra A, Caccavo D: Treatment of idiopathic mixed cryoglobulinemia with alpha interferon. Am J Med 83: 726–730, 1987.PubMedCrossRefGoogle Scholar
  131. 126.
    Durand JM, Kaplanski G, Lefevre P, Richard MA, Andrac L, Trepo C, Soubeyrand J: Effect of interferon-a 2b on cryoglobulinemia related to hepatitis C virus infection. J Infect Dis 165: 778–779, 1992.PubMedCrossRefGoogle Scholar
  132. 127.
    Sherlock S: The natural history of hepatitis B. Postgrad Med J 63: 7–11, 1987.PubMedCrossRefGoogle Scholar
  133. 128.
    Alter MJ, Favero MS, Maynard JE: Impact of infection control strategies of the incidence of dialysis-associated hepatitis in the United States. J Infect Dis 153: 1149–1151, 1986.PubMedCrossRefGoogle Scholar
  134. 129.
    Harnett JD, Zeldis JB, Parfrey PS, Kennedy M, Sirca R, Steinman TI, Guttman RD: Hepatitis B disease in dialysis and transplant patients. Transplantation 44: 369–376, 1987.PubMedCrossRefGoogle Scholar
  135. 130.
    Neilson JO, Dietrichson O, Elling P, Christofferson P: Incidence and meaning of persistence of Australia antigen in patients with acute viral hepatitis: development of chronic hepatitis. N Engl J Med 285: 1157–1160, 1971.CrossRefGoogle Scholar
  136. 131.
    Pao CC, Yang W-L, Huang C-C, Hsu J-L, Lin S-S, Ken R, Chao Y, Sun C-F, Liaw Y-F, Lin J-Y: Hepatitis Type B virus DNA in patients receiving hemodialysis: correlation with other HBV serological markers. Nephron 46: 155–160, 1987.PubMedCrossRefGoogle Scholar
  137. 132.
    Tokars JI, Alter MJ, Favero MS, Moyer LA, Bland LE: National surveillance of hemodialysis associated diseases in the United States 1990. ASAIO J 39: 71–80, 1993.PubMedGoogle Scholar
  138. 133.
    Stevens CE, Alter HJ, Taylor PE, Zang EA, Harley EJ, Szmuness W, and the Dialysis Vaccine Trial Study Group: Hepatitis B vaccine in patients receiving hemodialysis. N Engl J Med 311: 496–501, 1984.PubMedCrossRefGoogle Scholar
  139. 134.
    Köhler H, Arnold W, Renschin G, Dormeyer H-H, Büschenfelde K-H: Active hepatitis B vaccination of dialysis patients and medical staff. Kidney Int 25: 124–128, 1984.PubMedCrossRefGoogle Scholar
  140. 135.
    Dumann H, Meuer S, Büschenfelde K-H, Köhler H: Hepatitis B vaccination and interleukin 2 receptor expression in chronic renal failure. Kidney Int 38: 1164–1168, 1990.PubMedCrossRefGoogle Scholar
  141. 136.
    Pasko MT, Bartholomew WR, Beam TR, Amsterdam D, Cunningham EE: Long-term evaluation of the hepatitis B vaccine (Heptavax-B) in hemodialysis patients. Am J Kidney Dis 11: 326–331, 1988.PubMedGoogle Scholar
  142. 137.
    Buti M, Viladomiu L, Jardi R, Olmos A, Rodriguez JA, Bartolome J, Esteban R, Guardia J: Long-term immunogenecity and efficacy of hepatitis B vaccine in hemodialysis patients. Am J Nephrol 12: 144–147, 1992.PubMedCrossRefGoogle Scholar
  143. 138.
    Stevens CE, Szmuness W, Goodman AI, Weseley SA, Fotino, M: Hepatitis B vaccine: immune responses in hemodialysis patients. Lancet 2: 1211–1213, 1980.PubMedCrossRefGoogle Scholar
  144. 139.
    Sennesael JJ, Niepen P, Verbeeken DL: Treatment with recombinant human erythropoietin increases antibody titers after hepatitis B vaccination in dialysis patients. Kidney Int 40: 121–128, 1991.PubMedCrossRefGoogle Scholar
  145. 140.
    Meuer SC, Hauer M, Kurz P, Büschenfelde K-H, Köhler H: Selective blockade of the antigen-receptor-mediated pathway of T cell activation in patients with impaired primary immune responses. J Clin Invest 80: 743–749, 1987.PubMedCrossRefGoogle Scholar
  146. 141.
    Walz G, Kunzendorz U, Haller H, Keller F, Offermann G, Alasenic O: Factors influencing the response to hepatitis B vaccination of hemodialysis patients. Nephron 51: 474–477, 1989.PubMedCrossRefGoogle Scholar
  147. 142.
    Donati D, Gastaldi L: Controlled trial of thymopentin in hemodialysis patients who fail to respond to hepatits B vaccination. Nephron 50: 133–136, 1988.PubMedCrossRefGoogle Scholar
  148. 143.
    Melappioni M, Baldassani M, Saldini S, Radicioni R, Panichi N: Use of immunomodulators (thymopentine) in hepatitis B vaccine in elderly patients undergoing chronic hemodialysis. Nephron 61: 358–359, 1992.PubMedCrossRefGoogle Scholar
  149. 144.
    Moyer LA, Alter MJ, Favero MS: Hemodialysis-associated hepatitis B: revised recommendations for serologic screening. Sem in Dial 3: 201–204, 1990.CrossRefGoogle Scholar
  150. 145.
    Almeida JD, Waterson AP: Immune complexes in hepatitis. Lancet 2: 983–986, 1969.PubMedCrossRefGoogle Scholar
  151. 146.
    Nowoslowski A, Krawzynski K, Nazarewicz T, Slusarczyk T: Immunopathological aspects of hepatitis type B. Am J Med Sei 270: 229–239, 1975.CrossRefGoogle Scholar
  152. 147.
    Combes B, Stastny P, Shorey J, Eigenbrodt EM, Barrera A, Hull AR, Carter NW: Glomerulonephritis with deposition of Australia antigen-antibody complexes in glomerular basement membrane. Lancet 2: 234–237, 1971.PubMedCrossRefGoogle Scholar
  153. 148.
    Takekoshi Y, Shida N, Saheki Y, Tanaka M, Satake Y, Matsumoto S: Strong association between membranous nephropathy and hepatitis B surface antigenemia in Japanese children. Lancet 2: 1065–1068, 1978.PubMedCrossRefGoogle Scholar
  154. 149.
    Hsu H-C, Lin G-H, Chong M-H, Chen C-H: Assocation of hepatitis B surface (HBs) antigenemia and membranous nephropathy in children in Taiwan. Clin Nephrol 20: 121–129, 1983.PubMedGoogle Scholar
  155. 150.
    Yoshikawa N, Ito H, Yamada Y, Hashimoto H, Katayama Y, Matsuyama S, Hasegawa O, Okada S, Hajikano H, Yoshizawa H, Mayumi M, Matsuo T: Membranous glomerulonephritis associated with hepatitis B antigen in children: a comparison with idiopathic membranous glomerulonephritis. Clin Nephrol 23: 28–34, 1985.PubMedGoogle Scholar
  156. 151.
    Takekoshi Y, Tanaka M: Hepatitis B virus-associated glomerulonephritis in children. In: K Murakami, T Kitagawa, K Yabuta, T Sakai, eds, Recent Advances in Pediatric Nephrology. Excerpta Medica, New York, pp 293–298, 1987.Google Scholar
  157. 152.
    Lee HS, Choi Y, Yu SH, Koh HI, Kim MJ, Ko KW: A renal biopsy study of hepatitis B virus-associated nephropathy in Korea. Kidney Int 34: 537–543, 1988.PubMedCrossRefGoogle Scholar
  158. 153.
    Lai KN, Lai FM, Chan KW, Chow CB, Tong KL, Vallance- Owen J: The clinico-pathologic features of hepatitis B virus-associated glomerulonephritis. Q J Med 63: 323–333, 1987.PubMedGoogle Scholar
  159. 154.
    Chow CB, Leung NK: Membranous glomerulonephritis in Hong Kong (letter). Arch Dis Child 59: 693–694, 1984.PubMedCrossRefGoogle Scholar
  160. 155.
    Sham MK, Rune KK, Yeung CK, Ng NL, Change WK, Chan MK: Hepatitis B induced glomerulonephritis, fact or fiction? Aust NZJ Med 15: 356–358, 1985.CrossRefGoogle Scholar
  161. 156.
    Southwest Pediatric Nephrology Study Group: Hepatitis B surface antigenemia in North American children with membranous glomerulonephropathy. J Pediatr 10: 571–577, 1985.Google Scholar
  162. 157.
    Furuse A, Hattori S, Terashima T, Karashima S, Matsuda I: Circulating immune complex in glomerulo-nephropathy associated with hepatitis B virus infection. Nephron 31:212— 228, 1982.Google Scholar
  163. 158.
    Collins AB, Bhan AK, Dienstag JL, Colvin RB, Haupert GT, Mushahwar IK, McCluskey RT: Hepatitis B immune complex glomerulonephritis: simultaneous glomerular deposition of hepatitis B surface and e antigens. Clin Immunol Immunopathol 26: 137–153, 1983.PubMedCrossRefGoogle Scholar
  164. 159.
    Takekoshi Y, Tanaka M, Miyakawa Y, Yoshizawa H, Takahashi K, Mayumi M: Free “small” and IgG-associated “large” hepatitis B e antigen in the serum and glomerular capillary walls of two patients with membranous glomerulonephritis. N Engl J Med 300: 814–819, 1979.PubMedCrossRefGoogle Scholar
  165. 160.
    Takekoshi Y, Shida N, Saheki Y, Tanaka M, Satake Y, Matsumoto S: Strong association between membranous nephropathy and hepatitis-B surface antigenaemia in Japanese children. Lancet 2: 1065–1068, 1978.PubMedCrossRefGoogle Scholar
  166. 161.
    Team of the Asian Study of Renal Disease in Children: Clinical suvey of hepatits B antigenemia associated nephropathy in children. In: AB Gruskin, ME Norman, eds, Pediatric Nephrology (Proceedings of the Fifth International Pediatric Nephrology Symposium, held in Philadelphia, PA, October 6–10,1980). Martinus Nijhoff Publishers, The Hague/Boston/ London, pp 156–164, 1981.Google Scholar
  167. 162.
    Gregorek H, Jung H, Ulanowicz G, Madalinshi K: Immune complexes in sera of children with HCV-mediated glomerulonephritis. Arch Immunol Ther Exp 34: 73–83, 1986.Google Scholar
  168. 163.
    Johnson RJ, Couser WG: Hepatitis B infection and renal disease: clinical immunopathogenetic and therapeutic considerations. Kidney Int 37: 663–676, 1990.PubMedCrossRefGoogle Scholar
  169. 164.
    Myers BD, Griffel B, Naveh D, Jankielowitz T, Klajman A: Membranoproliferative glomerulonephritis associated with persistent viral hepatitis. Am J Clin Pathol 59: 222–228, 1973.Google Scholar
  170. 165.
    Knieser MR, Jenis EH, Lowenthal DT, Bancroft WH, Burns W, Shalhoub R: Pathogenesis of renal disease associated with viral hepatitis. Arch Pathol 97: 193–200, 1974.PubMedGoogle Scholar
  171. 166.
    Wysznska T, Jung H, Madalinski K, Morzycka M: Hepatits B mediated glomerulonephritis in children. Int J Pediatr Nephrol 5: 147–150, 1984.Google Scholar
  172. 167.
    Nagy J, Bajtai G, Brasch H, Süle T, Ambrus M, Deäk G, Hämori A: The role of hepatitis B surface antigen in the pathogenesis of glomerulopathies. Clin Nephrol 12: 109–116, 1979.PubMedGoogle Scholar
  173. 168.
    Lev M, Kleinkecht C, Droz D, Drueke T: Glomerular nephropathies and hepatitis B virus infection. In: J-F Bach, J Crosnier, J-L Funck-Brentano, J-P Grunfeld, MH Maxwell, eds, Advances in Nephrology, vol 11. Year Book Medical Publishers, Chicago, pp 341–370, 1982.Google Scholar
  174. 169.
    Brzosko W, Nazarewicz T, Krawczynski K, Morzycka M, Nowoslawski A: Glomerulonephritis associated with hepatitis-B surface antigen immune complexes in children. Lancet 2: 477–482, 1974.PubMedCrossRefGoogle Scholar
  175. 170.
    Amemiya S, Ito H, Kato K, Sakaguchi H, Hasegawa O, Hajikano H: A case of membranous proliferative glomerulonephritis type III (Burkholder) with the deposition of both HBeAg and HBsAg. Int J Pediatr Nephrol 4: 267–273, 1983.PubMedGoogle Scholar
  176. 171.
    Lai KN, Lai FM, Lo S, Ho CP, Chan KW: IgA nephropathy associated with hepatitis B virus antigenemia. Nephron 47: 141–143, 1987.PubMedCrossRefGoogle Scholar
  177. 172.
    Trepo C, Thivolet J: Hepatitis associated antigen and periarteritis nodosa (PAN). Vox Sang 19: 410–411, 1970.PubMedCrossRefGoogle Scholar
  178. 173.
    Gocke DJ, Hsu K, Morgan C, Bombardieri S, Lockshin M, Christian CL: Vasculitis in association with Australia antigen. J Exp Med 134: 330–335, 1971.PubMedGoogle Scholar
  179. 174.
    Sack M, Cassidy JT, Bole GG: Prognostic factors in polyarteritis. J Rheumatol 2:411-120,1975.Google Scholar
  180. 175.
    Ewald EA, Griffin D, McCune WJ: Correlation of angiographic abnormalities with disease manifestations and disease severity in polyarteritis nodosa. J Rheumatol 14: 952–956, 1987.PubMedGoogle Scholar
  181. 176.
    Cohen RD, Conn DT, Ilstrup DM: Clinical features, prognosis, and response to treatment in polyarteritis. Mayo Clin Proc 55: 146–155, 1980.PubMedGoogle Scholar
  182. 177.
    Fauci AS, Katz P, Haynes BF, Wolff SM: Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med 301: 235–238, 1979.PubMedCrossRefGoogle Scholar
  183. 178.
    Trepo CG, Zuckerman AJ, Bird RC, Prince AM: The role of circulating hepatitis B antigen/antibody immune complexes in the pathogenesis of vascular and hepatic manifestations in polyarteritis nodosa. J Clin Pathol 27: 863–868, 1974.PubMedCrossRefGoogle Scholar
  184. 179.
    Frohnert PP, Sheps SG: Long-term follow-up study of periarteritis nodosa. Am J Med 43: 8–14, 1967.PubMedCrossRefGoogle Scholar
  185. 180.
    Leib ES, Restivo C, Paulus HE: Immunosuppressive and corticosteroid therapy of polyarteritis nodosa. Am J Med 7: 941–947, 1979.CrossRefGoogle Scholar
  186. 181.
    Lai KN, Li PKT, Lui SF, Ch B, Au TG, Tam JSL, Tong KL, Lai F: Membranous nephropathy related to hepatitis B virus in adults. N Engl J Med 324: 1457–1463, 1991.PubMedCrossRefGoogle Scholar
  187. 182.
    Lin C-Y: Clinical features and natural course of HBV-related glomerulopathy in children. Kidney Int 40: S46 - S53, 1991.Google Scholar
  188. 183.
    Garcia G, Scullard G, Smith C, Weissberg, J, Alexander S, Robinson WS, Gregory P, Merigan TC: Preliminary observation of hepatitis B-associated membranous glomerulonephritis treated with leukocyte interferon. Hepatology 5: 317–320, 1985.PubMedCrossRefGoogle Scholar
  189. 184.
    Mizushima N, Kanai K, Matsuda H, Matsumoto M, Tamakoshi K, Hidemasa I, Nakajima T, Yoshimi T, Kimura M, Nagase M: Improvement of proteinuria in a case of hepatitis B-associated glomeruloepphritis after treatment with interferon. Gastroenterology 92: 524–526, 1987.PubMedGoogle Scholar
  190. 185.
    De Man RA, Schalm SW, Van Der Heijden AJ, Ten Kate FWJ, Wolff ED, Heijtink RA: Improvement of hepatitis B- associated glomerulonephritis after antiviral combination therapy. J Hepatol 8: 367–372, 1989.PubMedCrossRefGoogle Scholar
  191. 186.
    Lisker-Melman M, Webb D, Di Bisceglie AM, Kassianides C, Martin P, Rustgi V, Waggoner JG, Park Y, Hoofnagle JH: Glomerulonephritis caused by chronic hepatitis B virus infection: treatment with recombinant human alpha-interferon. Ann Intern Med 111: 479–483, 1989.PubMedCrossRefGoogle Scholar
  192. 187.
    Esteban R, Buti M, Valles M, Allende H, Guardia J: Hepatitis B-associated membranous glomerulonephritis treated with adenine arabinoside monophosphate (letter). Hepatology 6: 762–763, 1986.PubMedCrossRefGoogle Scholar
  193. 188.
    Lin C-Y, Lo S: Treatment of hepatitis B virus-associated membranous nephropathy with adenine arabinoside and thymic extract. Kidney Int 39: 301–306, 1991.PubMedCrossRefGoogle Scholar
  194. 189.
    Pol S, Debure A, Degott C, Carnot F, Legendre C, Brechot C, Kreis H: Chronic hepatitis in kidney allograft recipients. Lancet 335: 878–880, 1990.PubMedCrossRefGoogle Scholar
  195. 190.
    Parfrey PS, Forbes RDC, Hutchinson TA, Kenick S, Farge D, Dauphinee WD, Seely JF, Guttman RD: The impact of renal transplantation on the course of hepatitis B liver disease. Transplantation 39: 610–615, 1985.PubMedCrossRefGoogle Scholar
  196. 191.
    Parfrey PS, Forbes RDC, Hutchinson TA, Beaudoin JG, Dauphinee WD, Hollomby DJ, Guttman RD: The clinical and pathological course of hepatitis B liver disease in renal transplant recipients. Transplantation 37: 461–466, 1984.PubMedCrossRefGoogle Scholar
  197. 192.
    Degos F, Degott C, Bedrossian J, Camilieri JP, Barbanel C, Dubour A, Rueff B, Benhamou JP, Kreis H: Is renal transplantation involved in post-transplantation liver disease? Transplantation 29: 100–102, 1980.PubMedCrossRefGoogle Scholar
  198. 193.
    Roth D: Hepatitis C virus: The Nephrologist’s view. Am J Kid Dis 25: 3–16, 1995.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • David Roth
    • 1
  • Guido Perez
    • 1
  1. 1.The Veterans Administration Medical Center, Division of Nephrology (R-126)University of Miami School of MedicineMiamiUSA

Personalised recommendations